vs
UNITED THERAPEUTICS Corp（UTHR）与伟世通（VC）财务数据对比。点击上方公司名可切换其他公司
伟世通的季度营收约是UNITED THERAPEUTICS Corp的1.2倍（$948.0M vs $790.2M），UNITED THERAPEUTICS Corp净利率更高（46.1% vs 7.8%，领先38.3%），UNITED THERAPEUTICS Corp同比增速更快（7.4% vs 1.0%），过去两年UNITED THERAPEUTICS Corp的营收复合增速更高（8.0% vs 0.8%）
United Therapeutics是美国生物技术企业，专注开发包含异种移植在内的器官移植相关药物与技术，多款产品布局肺部疾病及器官制造赛道，双总部位于马里兰州银泉与北卡罗来纳州三角研究园，在美加多地设有研发及运营分支机构。
伟世通是一家总部位于美国密歇根州范布伦镇区的全球性汽车电子供应商，业务涵盖汽车座舱电子产品、车联网服务以及电动化相关产品的设计、研发与制造，客户几乎覆盖全球所有主流汽车制造商。
UTHR vs VC — 直观对比
营收规模更大
VC
是对方的1.2倍
$790.2M
营收增速更快
UTHR
高出6.4%
1.0%
净利率更高
UTHR
高出38.3%
7.8%
两年增速更快
UTHR
近两年复合增速
0.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $790.2M | $948.0M |
| 净利润 | $364.3M | $74.0M |
| 毛利率 | 86.9% | 12.9% |
| 营业利润率 | 45.1% | 6.9% |
| 净利率 | 46.1% | 7.8% |
| 营收同比 | 7.4% | 1.0% |
| 净利润同比 | 20.9% | -40.8% |
| 每股收益（稀释后） | $7.66 | $2.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收UTHRVC
| Q4 25 | $790.2M | $948.0M | ||
| Q3 25 | $799.5M | $917.0M | ||
| Q2 25 | $798.6M | $969.0M | ||
| Q1 25 | $794.4M | $934.0M | ||
| Q4 24 | $735.9M | $939.0M | ||
| Q3 24 | $748.9M | $980.0M | ||
| Q2 24 | $714.9M | $1.0B | ||
| Q1 24 | $677.7M | $933.0M |
净利润UTHRVC
| Q4 25 | $364.3M | $74.0M | ||
| Q3 25 | $338.7M | $-11.0M | ||
| Q2 25 | $309.5M | $71.0M | ||
| Q1 25 | $322.2M | $67.0M | ||
| Q4 24 | $301.3M | $125.0M | ||
| Q3 24 | $309.1M | $40.0M | ||
| Q2 24 | $278.1M | $83.0M | ||
| Q1 24 | $306.6M | $48.0M |
毛利率UTHRVC
| Q4 25 | 86.9% | 12.9% | ||
| Q3 25 | 87.4% | 14.3% | ||
| Q2 25 | 89.0% | 14.6% | ||
| Q1 25 | 88.4% | 14.8% | ||
| Q4 24 | 89.7% | 14.3% | ||
| Q3 24 | 88.9% | 13.4% | ||
| Q2 24 | 89.1% | 14.5% | ||
| Q1 24 | 89.2% | 12.8% |
营业利润率UTHRVC
| Q4 25 | 45.1% | 6.9% | ||
| Q3 25 | 48.6% | 8.8% | ||
| Q2 25 | 45.6% | 10.0% | ||
| Q1 25 | 48.2% | 10.2% | ||
| Q4 24 | 48.6% | 8.9% | ||
| Q3 24 | 45.8% | 5.2% | ||
| Q2 24 | 44.7% | 9.9% | ||
| Q1 24 | 52.6% | 6.8% |
净利率UTHRVC
| Q4 25 | 46.1% | 7.8% | ||
| Q3 25 | 42.4% | -1.2% | ||
| Q2 25 | 38.8% | 7.3% | ||
| Q1 25 | 40.6% | 7.2% | ||
| Q4 24 | 40.9% | 13.3% | ||
| Q3 24 | 41.3% | 4.1% | ||
| Q2 24 | 38.9% | 8.2% | ||
| Q1 24 | 45.2% | 5.1% |
每股收益（稀释后）UTHRVC
| Q4 25 | $7.66 | $2.67 | ||
| Q3 25 | $7.16 | $-0.40 | ||
| Q2 25 | $6.41 | $2.57 | ||
| Q1 25 | $6.63 | $2.44 | ||
| Q4 24 | $6.23 | $4.50 | ||
| Q3 24 | $6.39 | $1.43 | ||
| Q2 24 | $5.85 | $2.97 | ||
| Q1 24 | $6.17 | $1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.9B | $771.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $7.1B | $1.6B |
| 总资产 | $7.9B | $3.4B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资UTHRVC
| Q4 25 | $2.9B | $771.0M | ||
| Q3 25 | $2.8B | $762.0M | ||
| Q2 25 | $3.0B | $668.0M | ||
| Q1 25 | $3.3B | $655.0M | ||
| Q4 24 | $3.3B | $623.0M | ||
| Q3 24 | $3.3B | $550.0M | ||
| Q2 24 | $3.0B | $505.0M | ||
| Q1 24 | $2.7B | $504.0M |
股东权益UTHRVC
| Q4 25 | $7.1B | $1.6B | ||
| Q3 25 | $6.6B | $1.5B | ||
| Q2 25 | $7.2B | $1.5B | ||
| Q1 25 | $6.8B | $1.4B | ||
| Q4 24 | $6.4B | $1.3B | ||
| Q3 24 | $6.1B | $1.3B | ||
| Q2 24 | $5.7B | $1.2B | ||
| Q1 24 | $5.3B | $1.1B |
总资产UTHRVC
| Q4 25 | $7.9B | $3.4B | ||
| Q3 25 | $7.4B | $3.3B | ||
| Q2 25 | $7.9B | $3.3B | ||
| Q1 25 | $7.7B | $3.1B | ||
| Q4 24 | $7.4B | $3.0B | ||
| Q3 24 | $7.1B | $3.0B | ||
| Q2 24 | $6.7B | $2.8B | ||
| Q1 24 | $6.5B | $2.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $346.2M | $118.0M |
| 自由现金流经营现金流 - 资本支出 | $173.3M | — |
| 自由现金流率自由现金流/营收 | 21.9% | — |
| 资本支出强度资本支出/营收 | 21.9% | — |
| 现金转化率经营现金流/净利润 | 0.95× | 1.59× |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流UTHRVC
| Q4 25 | $346.2M | $118.0M | ||
| Q3 25 | $562.1M | $127.0M | ||
| Q2 25 | $191.7M | $95.0M | ||
| Q1 25 | $461.2M | $70.0M | ||
| Q4 24 | $341.2M | $203.0M | ||
| Q3 24 | $377.2M | $98.0M | ||
| Q2 24 | $232.2M | $57.0M | ||
| Q1 24 | $376.5M | $69.0M |
自由现金流UTHRVC
| Q4 25 | $173.3M | — | ||
| Q3 25 | $351.6M | — | ||
| Q2 25 | $129.5M | — | ||
| Q1 25 | $386.3M | — | ||
| Q4 24 | $254.5M | — | ||
| Q3 24 | $300.7M | — | ||
| Q2 24 | $187.1M | — | ||
| Q1 24 | $338.3M | — |
自由现金流率UTHRVC
| Q4 25 | 21.9% | — | ||
| Q3 25 | 44.0% | — | ||
| Q2 25 | 16.2% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 34.6% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | 26.2% | — | ||
| Q1 24 | 49.9% | — |
资本支出强度UTHRVC
| Q4 25 | 21.9% | — | ||
| Q3 25 | 26.3% | — | ||
| Q2 25 | 7.8% | — | ||
| Q1 25 | 9.4% | — | ||
| Q4 24 | 11.8% | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 6.3% | — | ||
| Q1 24 | 5.6% | — |
现金转化率UTHRVC
| Q4 25 | 0.95× | 1.59× | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 0.62× | 1.34× | ||
| Q1 25 | 1.43× | 1.04× | ||
| Q4 24 | 1.13× | 1.62× | ||
| Q3 24 | 1.22× | 2.45× | ||
| Q2 24 | 0.83× | 0.69× | ||
| Q1 24 | 1.23× | 1.44× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
UTHR
| Tyvaso DPI | $338.6M | 43% |
| Remodulin | $128.0M | 16% |
| Nebulized Tyvaso | $125.7M | 16% |
| Orenitram | $121.2M | 15% |
| Unituxin | $62.3M | 8% |
| Adcirca | $7.8M | 1% |
| Other | $6.6M | 1% |
VC
| Audioandinfotainment | $508.0M | 54% |
| Informationdisplays | $428.0M | 45% |
